[Featured Stock] SuzenTec Rises 5 Consecutive Days on FDA Approval of COVID Antibody Test Kit

[Image source=Yonhap News]

[Asia Economy Reporter Eunmo Koo] SuzenTech has continued its upward trend, rising for five consecutive trading days. The news of the emergency use authorization by the U.S. Food and Drug Administration (FDA) for its COVID-19 antibody rapid diagnostic kit appears to be influencing this rise.

As of 11:10 AM on the 8th, SuzenTech was trading at 59,300 KRW, up 9.01% (4,900 KRW) from the previous trading day. During the session, the price briefly rose to 65,800 KRW, setting a new 52-week high.

The day before, SuzenTech announced that its COVID-19 antibody rapid diagnostic kit, 'SGTi-flex IgG,' passed the performance evaluation by the U.S. National Cancer Institute (NCI) and became the first in Korea to receive emergency use authorization from the U.S. FDA. Globally, only 14 antibody rapid diagnostic kits, including SuzenTech's, have received FDA emergency use authorization, and SuzenTech's product is the only domestic rapid diagnostic kit among them.

SuzenTech's COVID-19 antibody rapid diagnostic kit recorded a sensitivity of 97% and specificity of 100% in the NCI performance evaluation conducted during the FDA approval process. These figures exceed the U.S. FDA approval standards of 90% sensitivity and 95% specificity.

This content was produced with the assistance of AI translation services.